Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis

Exclusion Criteria

• •1. patients who had been treated with UDCA, immunosuppressive medications within 3 months.
• •2. patients who had evidence of extrahepatic biliary obstruction
• •3. patients coinfection with HBV or HCV
• •4. patients with one of the followings: 1) hemoglobin(HB): \<11 g/dl in male, \<10 g/dl in female 2) white blood cell count \<3000/mm3 3) neutrophile granulocyte \<1500/mm3 4) platelet \<50000/mm3; 5) serum albumin \<3.3 g/dl 6) alanine aminotransferase(ALT)≥10×ULN and/or aspartate aminotransferase(ALT)≥10×ULN; 7) ALT≥5×ULN and/or AST≥5×ULN coexisting with immunoglobulin G (IgG) ≥2×ULN; 8) total bilirubin ≥4×ULN; 9) prothrombin time (PT) prolong 3 seconds or more, or PTA ≦60%; 10) creatinine ≥4×ULN.
• •5. patients with evidence of decompensated liver disease(ascites, gastrointestinal bleeding, hepatic encephalopathy et al.)
• •6. definitely diagnosed as hepatocellular carcinoma(HCC), probable HCC, AFP\>100ng/ml.Patients with AFP\>2×ULN while \<100ng/ml should re-test 2 weeks later.
• •7. Body Mass Index \>28 kg/m2
• •8. drug or alcohol abuse.
• •9. patient with severe disease of heart, lung, kidney, alimentary canal, neural system, autoimmune disease or tumor
• •10. patient had or on the scheduled of organ transplantation;
• •11. patient for whom the follow-up is considered impossible
• •12. pregnant or nursing woman